NVCT — Nuvectis Pharma Inc
NASDAQ · Healthcare · Biotechnology
$23.06
+$0.33 (+1.45%)
Nuvectis Pharma Inc (NVCT) is a biotechnology company listed on NASDAQ. It is led by Ron Bentsur M.B.A., based in 1 Bridge Plaza, Fort Lee, NJ, United States, 07024, with about 12 employees. Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Net income was -$19.1M. NVCT currently screens at market cap $304.5M.
Use this NVCT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NVCT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NVCT SEC filings page. Lician reads the product cache first so this HTML stays unique to Nuvectis Pharma Inc even when a live quote feed is slow.
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
NVCT Key Statistics
Market Cap
$304.51M
Volume
276,371
Previous Close
$23.87
Day Range
$23.85 – $25.94
P/B Ratio
20.84
EPS
-$1.11
Revenue
$0.00
Net Income
-$19.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
12
NVCT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$19.00M | -$22.26M | -$19.09M | -$12.89M |
| EPS (Diluted) | -$1.11 | -$1.43 | -$1.51 | -$3.02 |
Total Assets
$18.61M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$18.53M
Operating Cash Flow
-$12.25M
Free Cash Flow
$0.00
Nuvectis Pharma Inc Company Information
- Co-Founder, Chairman, CEO & President
- Ron Bentsur M.B.A.
- Headquarters
- 1 Bridge Plaza, Fort Lee, NJ, United States, 07024
- Website
- www.nuvectis.com
- Phone
- 201 614 3150
- IPO / Founded
- 2022-02-04
- Sector
- Healthcare
- Industry
- Biotechnology